Table 2.
Deregulated expression of CDC20 and its involvement as prognostic and therapeutic target in hematological malignancies
| Cancer type | Evidence in primary samples | Impact on prognosis | Pre-clinical studies | Ref. |
|---|---|---|---|---|
| ATL |
CDC20 over-expression in ATL samples compared with normal CD4+ T cells. Aberrant activation of APC/CCDC20 induced by Tax |
[116, 117] | ||
| AML | CDC20 over-expression in aneuploid and complex karyotype patients. | [118, 119] | ||
| CLL | CDC20 over-expression in aggressive subtypes (U-CLL and CD38+ CLL). | [120, 121] | ||
| CML | CDC20 stabilization induced by CDH1down-regulation in imatinib-resistance patients | [122] | ||
| DLBCL | CDC20 over-expression | Inferior OS | proTAME induces prolonged metaphase and caspase-dependent apoptosis. Combination of proTAME with Apcin, doxorubicin and venetoclax show synergic effects. | [123, 124] |
| MCL | CDC20 over-expression | Inferior OS | proTAME induces prolonged metaphase and caspase-dependent apoptosis. Combination of proTAME with Apcin, doxorubicin and venetoclax show synergic effects. | [124, 125] |
| MDS | CDC20 over-expression in high-risk patients | Shorter RFS and inferior OS | [126–128] | |
| MM | CDC20 over-expression in cell lines and high-risk patients | Inferior OS | proTAME treatment induced G2/M arrest and increased apoptosis. Combination with etoposide and doxorubicin, vincristine or melphalan potentiated proTAME effect. | [129–132] |